2017 saw the publication of new classifications for epilepsy and seizure types, which emphasize the importance of understanding the underlying disease mechanisms. This aetiology-based approach is already beginning to inform developments in therapies and trial design in the epilepsies.
This is a preview of subscription content, access via your institution
Subscribe to Nature+
Get immediate online access to the entire Nature family of 50+ journals
Subscribe to Journal
Get full journal access for 1 year
only $8.25 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Get time limited or full article access on ReadCube.
All prices are NET prices.
Scheffer, I. E. et al. ILAE classification of the epilepsies: position paper of the ILAE Commission for Classification and Terminology. Epilepsia 58, 512–521 (2017).
Fisher, R. S. et al. Operational classification of seizure types by the International League Against Epilepsy: position paper of the ILAE commission for classification and terminology. Epilepsia 58, 522–530 (2017).
Fisher, R. S. et al. Instruction manual for the ILAE 2017 operational classification of seizure types. Epilepsia 58, 531–542 (2017).
[No authors listed]. Proposal for revised classification for epilepsies and epileptic syndromes. Epilepsia 30, 389–399 (1989).
Devinsky, O. et al. Cannabidiol in patients with treatment-resistant epilepsy: an open-label intervention trial. Lancet Neurol. 15, 270–278 (2016).
Devinsky, O. et al. Trial of cannabidiol for drug-resistant seizures in the Dravet syndrome. N. Engl. J. Med. 376, 2011–2020 (2017).
Wu, Y. W. et al. Incidence of Dravet syndrome in a US population. Pediatrics 136, e1310–e1315 (2015).
Dwivedi, R. et al. Surgery for drug-resistant epilepsy in children. N. Engl. J. Med. 377, 1639–1647 (2017).
Kim, D. W. et al. Surgical treatment of non-lesional neocortical epilepsy: long-term longitudinal study. JAMA Neurol, 74, 324–331 (2017).
O'Callaghan, F. J. et al. Safety and effectiveness of hormonal treatment versus hormonal treatment with vigabatrin for infantile spasms (ICISS): a randomised, multicentre, open-label trial. Lancet Neurol. 16, 33–42 (2017).
S.M.Z. has received honoraria for educational activities and advisory boards from GW Pharma, paid to his institution's charitable account. He was Chair of the International League Against Epilepsy Commission for Classification and Terminology from 2013–2017. A.B. declares no competing interests.
About this article
Cite this article
Zuberi, S., Brunklaus, A. Precision medicine drives epilepsy classification and therapy. Nat Rev Neurol 14, 67–68 (2018). https://doi.org/10.1038/nrneurol.2017.190
Nature Reviews Neurology (2020)